Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Active Biotech

0,07 SEK

+7,97 %

Mindre end 1K følgere

ACTI

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
+7,97 %
+1,26 %
-50,89 %
-68,61 %
-24,71 %
-43,11 %
-80,59 %
-83,86 %
-98,43 %

Active Biotech operates in the pharmaceutical industry and focuses on the development of innovative treatments for cancer and autoimmune diseases. The company researches new therapies that can improve patient outcomes and quality of life. The project portfolio includes both small, orally active immunomodulatory molecules and antibody-based immunotherapy. The company operates globally. Active Biotech was founded in 1998 and is headquartered in Lund.

Læs mere
Markedsværdi
171,34 mio. SEK
Aktieomsætning
1,21 mio. SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
12.2
2026

Årsrapport '25

7.5
2026

Delårsrapport Q1'26

20.5
2026

Generalforsamling '26

Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse25.11.2025, 09.00

Active Biotech’s patent related to a pharmaceutical formulation of tasquinimod will be granted in the US

Active Biotech
Selskabsmeddelelse25.11.2025, 07.30

The subscription period in Active Biotech’s rights issue begins today

Active Biotech
Pressemeddelelse24.11.2025, 08.30

Positive preclinical tasquinimod data in myelofibrosis published in Blood Advances

Active Biotech

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse20.11.2025, 14.45

Active Biotech publishes information document regarding rights issue

Active Biotech
Selskabsmeddelelse19.11.2025, 11.00

Extraordinary General Meeting of Active Biotech AB

Active Biotech
Pressemeddelelse10.11.2025, 08.45

Redeye: Active Biotech (Q3 Review) - Rights Issue Funds 2026-2027

Active Biotech
Selskabsmeddelelse6.11.2025, 07.30

Active Biotech Interim Report Q3 2025

Active Biotech
Pressemeddelelse3.11.2025, 15.30

Preclinical data of tasquinimod in combination with T cell activation to be presented at ASH 2025

Active Biotech
Selskabsmeddelelse17.10.2025, 18.35

NOTICE OF EXTRAORDINARY GENERAL MEETING

Active Biotech
Selskabsmeddelelse17.10.2025, 18.30

Active Biotech announces a fully secured rights issue of approximately SEK 70 million

Active Biotech
Pressemeddelelse10.9.2025, 11.00

Positive results from Active Biotech’s clinical phase I LION study to be presented at AAO 2025 in October

Active Biotech
Pressemeddelelse25.8.2025, 14.40

Redeye: Active Biotech Q2 2025 - On the Eve of a Laquinimod Deal

Active Biotech
Selskabsmeddelelse21.8.2025, 06.30

INTERIM REPORT Q2 2025

Active Biotech
Pressemeddelelse8.7.2025, 06.30

Active Biotech provides status update of its development programs

Active Biotech
Pressemeddelelse30.6.2025, 15.15

Interview with investigators of laquinimod eye drop study LION now available on Active Biotech’s website

Active Biotech
Pressemeddelelse9.6.2025, 14.50

Results from tasquinimod study in heavily pretreated patients with relapsed refractory multiple myeloma presented at ASCO 2025 available on Active Biotech’s website

Active Biotech
Selskabsmeddelelse28.5.2025, 16.30

Annual General Meeting of Active Biotech AB

Active Biotech
Pressemeddelelse23.5.2025, 06.30

Active Biotech reports study results with tasquinimod in heavily pre-treated patients with relapsed refractory multiple myeloma

Active Biotech
Pressemeddelelse21.5.2025, 06.30

Active Biotech announces patent for tasquinimod in myelofibrosis granted in Europe

Active Biotech
Pressemeddelelse11.5.2025, 15.59

Redeye: Active Biotech Q1 2025 - Important results with laquinimod

Active Biotech
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.